Table 2 prognostic factors of distant progression free survival and overall survival

PET-TDM

0.59

0.44

[0.20,0.94]

0.068

Oligometastatic site

0.136

0.02

0.37

Indication (oligometastatic spectrum) (ref = oligometastases)

0.04

0.029

0.03

0.02

Center

0.498

0.477

Age (ref= > 63 y)

0.69

[0.43,1.12]

0.134

0.42

[0.23,0.76]

0.004

0.003

Gender (ref = male)

0.89

[0.55,1.46]

0.65

1.11

[0.62,1.98]

0.731

Smoking habits

0.66

[0.34,1.26]

0.226

1.25

[0.53,2.95]

0.593

Comorbidities

0.999

[0.61,1.65]

0.992

1.42

[0.78,2.57]

0.223

Free interval (ref > 516 days)

2.41

[1.28,4.51]

0.001

3.23

[1.37,7.61]

0.002

Primary cancer controlled

1.24

[0.63,2.44]

0.498

1.14

[0.48,2.70]

0.77

Number of metastatic lesions =2 (ref = 1)

1.18

[0.53,2.60]

0.695

0.962

[0.38,2.43]

0.928

Number of previous systemic treatment lines

0.777

0.133

Synchronous lesion (ref = metachronous)

0.90

[0.53,1.54]

0.716

1.09

[0.60,1.99]

0.779

Histology

0.985

0.685

EGFR mutation or ALK translocation

1.56

[0.77,3.15]

0.252

0.83

[0.37,1.85]

0.581

 T2

1.3

[0.66,2.58]

0.2

1.79

[0.73,4.4]

0.02

0.008

 T3

0.8

[0.39,1.75]

0.79

[0.29,2.2]

 T4

1.9

[0.84,4.5]

3

[1.05,8.4]

Initial N+ status (ref = N0)

1.71

[1.01,2.90]

0.035

0.022

1.29

[0.69,2.425]

0.411